Exelixis (EXEL) Tops Q3 EPS by 3c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020 4:05 PM EST- Total Revenues of $231.1 Million, Cabozantinib Franchise Revenues of $168.6 Million -
- GAAP Diluted EPS of $(0.10), Non-GAAP Diluted EPS of $0.04 -
- Conference Call and Webcast Today at 5:00 PM Eastern Time -
ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
In the third quarter of 2020, the Exelixis... More
